Neumora starts Phase 1 study of second M4 PAM, NMRA-898; no convulsions in preclinical

Neumora Therapeutics, Inc.

Initiated Phase 1 SAD/MAD study of NMRA-898, an M4 positive allosteric modulator for schizophrenia and neuropsychiatric disorders.
NMRA-898 is structurally distinct from NMRA-861 (Phase 1 started July 2025); both may offer best-in-class pharmacology.
No convulsions observed in preclinical studies across multiple species, including rabbits.
Neumora expects to provide a comprehensive M4 franchise update by mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.